AbCellera Biologics
Biotech focused on antibody treatments
- 501-1000 employees
- B2B
- Artificial Intelligence
- Biology
- Science
- MedTech
- Mount Pleasant, Vancouver, BC
Jump to section
Company mission
To improve health with technologies that transform the way that antibody-based therapies are discovered.
35% employee growth in 12 months
Our take
Antibody discovery is the process by which antibodies are identified that bind to specific disease targets, enabling treatments for those diseases to be developed. AbCellera provides an AI-powered platform for antibody discovery, to help speed up the creation of such treatments.
As the pharmaceutical world continues to embrace AI, there is immense opportunity for AbCellera. The company already scored a big win back in 2020 by helping Eli Lilly identify the antibody it would use in its COVID-19 treatment. Now, it looks to execute its 100 or so discovery programs for new drugs from which it can hope to earn millions in royalties.
The challenge for AbCellera, like many startups in the space, will be staying ahead of the curve in the application of emerging technologies while maintaining total compliance with regulations. So far signs are encouraging, with steady revenue improvements and a number of partnerships under its belt.
Steph
Company Specialist at Welcome to the Jungle
Benefits
- Immigration & Relocation Assistance - Get you (and your family) settled into a new city with the help of our team, including personalized immigration support
- Work-Life Balance - Take the time you need to support yourself and your family.
- Health Benefits - Stay well with a comprehensive health benefits package that includes health, dental, life and critical illness coverage
- Stock Options - Work together, win together with an ownership stake in AbCellera.
- Active Lifestyle Allowance - Use the active lifestyle allowance for the fitness activities that keep you active and healthy
- Paid Vacation - You work hard and should take well-deserved time off, starting with a minimum of 3 weeks' vacation
- Flexible Work Hours - Optimize how you work with flexible work hours.
- Personal & Professional Development - Ignite your curiosity, learn and be inspired through workshops, conferences and programs
Funding (last 2 of 8 rounds)
May 2023
$512.6m
GRANT
May 2020
$105.3m
SERIES B
Total funding: $636.6m
This company has top investors
Leadership
Carl Hansen
(CEO)Until August 2019, Carl was a Professor at the University of British Columbia, where they co-authored over 65 papers in the fields of microfluidics, immunology, genomics, and nanotechnology. Before leading AbCellera, they were a scientific Co-Founder of Precision Nanosystems, and served on the SAB of Fluidigm Corp.
Véronique Lecault
(CTO & Co-founder)Véronique received their PhD in Chemical and Biological Engineering from the University of British Columbia, where they co-invented the high-throughput microfluidic platform that is now part of AbCellera’s core technology. They are a recipient of the L’Oreal-UNESCO For Women in Science Mentorship Award.